Background: Real-time (RT) PCR is a rapid and accurate method that is widely used for the detection of Mycobacterium tuberculosis complex (MTB). The aim of this study was to evaluate and compare the performance of the Genedia MTB/NTM Detection Kit and the Anyplex plus MTB/NTM Detection kit in the detection of MTB and nontuberculous mycobacteria (NTM) in clinical specimens. Methods: From October 2017 to February 2018, 236 respiratory specimens and 137 non-respiratory specimens, from patients with suspected tuberculosis, were examined. AFB smear, culture, and RT-PCR using the Genedia MTB/NTM Detection kit (Green Cross Medical Science Corp.) and the Anyplex plus MTB/NTM Detection kit (Seegene) were applied. PCR performance in the detection of MTB and NTM was evaluated in relation to culture results and between the two assays.
| INTRODUC TI ON
Worldwide, tuberculosis (TB) is one of the top 10 causes of death and the leading cause from a single infectious disease. In 2017, there were an estimated 1.3 million deaths due to TB among HIV-negative people and an additional 300 000 deaths among HIV-positive people. About 6.4 million new cases of TB were officially notified to the World Health Organization (WHO) via national authorities, although TB incidence and mortality rates are gradually decreasing
year after year. 1 Mycobacterium tuberculosis, the causative agent of tuberculosis, can be detected using a variety of methods, such as acid-fast bacillus (AFB) staining, culture, and PCR. Specifically, molecular methods, using PCR-based techniques, can be used to obtain accurate results in a short period of time and are typically used in conjunction with conventional culture and microscopy-based methods. 2 The Genedia MTB/NTM Detection kit (Green Cross Medical Science Corp.) was developed for the rapid molecular detection of the M tuberculosis complex (MTB) and nontuberculous mycobacteria (NTM). The Genedia assay is a real-time (RT) PCR method targeting IS6110 with TaqMan hydrolysis probes for MTB and the rpoB gene for NTM. In this present study, we evaluated the performance of the Genedia kit using clinical respiratory specimens as well as non-respiratory specimens. Then, we compared the results with the Anyplex plus MTB/NTM Detection kit (Seegene).
| MATERIAL S AND ME THODS

| Samples
We selected respiratory and non-respiratory samples that were transferred to the Department of Laboratory Medicine in a tertiary university hospital for MTB/NTM PCR from October 2017 to February 2018.
All clinical samples were examined by AFB smear, conventional culture, and RT-PCR. This study was approved by the institutional review board of Chungnam National University Hospital.
| AFB smear and culture
Respiratory specimens were treated with NALC-NaOH (2% N-acetyl-L-cysteine-sodium hydroxide) after centrifugation at 3000 × g for 20 minutes. The AFB smear procedure involved staining with auramine-rhodamine fluorescent stain, followed by confirmation using Ziehl-Neelsen staining. Smears were graded, and those from 1 to 4 were defined as smear-positive. All specimens were cultured in liquid (MGIT960 system) and solid (2% Ogawa agar) media for a maximum of 6 and 8 weeks, respectively. Identification of MTB and NTM was carried out by MPT 64 antigen detection using immunochromatographic method. 
| Real-time PCR kits
| Statistical analyses
Sensitivity, specificity, positive predictive value, and negative predictive value were organized using Microsoft Excel 2013 software Specimens were examined by AFB smear, culture, and using both RT-PCR tests. Of these, 37 (9.9%) were AFB-positive, including 36 respiratory specimens and 1 synovial fluid specimen; the remaining 337 (90.3%) specimens were AFB-negative (Table 1) .
| RE SULTS
Of the 236 respiratory specimens cultured, 26 (11.0%) were positive for MTB and 22 (9.3%) were positive for NTM. Of the 137 non-respiratory specimens cultured, 4 (2.9%) were positive for MTB and 1 (0.7%) for NTM. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of each assay were calculated using the culture results as the "gold standard" (Table 1) The degree of agreement between the two PCR assays in the detection of both MTB and NTM was measured by calculating the kappa (κ) coefficient. The value of kappa is 0.836, which is a statistically high agreement ( Table 2 ).
| D ISCUSS I ON
We evaluated the performance of the Genedia MTB/NTM Detection kit compared with the Anyplex plus MTB/NTM Detection kit.
According to the results, sensitivity and specificity in MTB were 76.7% and 99.7% in Genedia, and 86.7% and 97.5 in Anyplex, respectively. Sensitivity and specificity in NTM were 73.9% and 100.0% in Genedia, and 73.9% and 99.4% in Anyplex, respectively. There were no statistically significant differences between the two tests.
A previous evaluation of the Genedia assay for MTB detection in respiratory samples reported sensitivity and specificity as 81.8% and 99.8%, respectively. 6 Sensitivity and specificity of the Anyplex assay for detection of MTB in respiratory specimens have been reported as 87.5% and 98.2%. 7 For both respiratory and non-respiratory specimens, sensitivity and specificity were 71.0% and 94.9%. 8 We found that sensitivity of both kits was lower with AFB smearnegative samples, which is consistent with previous findings. Nine false-positive results were detected in AFB smear-negative specimens using the Anyplex assay, resulting in a lower PPV (76.5%) than that of the Genedia assay (95.8%). In another previous study, the TAT (Turn Around Time) of Genedia kit was about 140 minutes and showed high correlation and accuracy with conventional PCR and other real-time PCR methods (AdvanSure kit, Real-Q kit). 9
In this study, the specificity and NPV calculated for AFB smear-positive specimens were significantly lower than those for smear-negative specimens. This may be due to the small number of specimens, which is a limitation of this study. and specificity than the initial product launch and have been used in many clinical laboratories with the advantage of obtaining rapid results. 5 In summary, both the Genedia MTB/NTM Detection kit (Green Cross Medical Science) and the Anyplex plus MTB/NTM Detection kit (Seegene) have the capacity to report high sensitivity and specificity in a short time and both demonstrate a high concordance rate. We therefore propose that these kits can be used more widely in clinical laboratories. It is considered necessary to study the problem of increased false-positive rate when targeting AFB-negative samples. Further research is needed in near future, including identification of non-detected and false-positive samples in larger numbers of specimens.
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